Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 6/20 | 0.54 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.54 |
| ▸ | NAMPT | P43490 | 8/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3730702 | 0.96 | NAMPT (0.56) | PRMT5WDR77NAMPTDRD2DRD3 | |
| SCHEMBL22545843 | 0.78 | PRMT5 (0.72) | PRMT5WDR77NAMPTDRD2DRD3 | |
| SCHEMBL4513205 | 0.77 | DRD3 (0.74) | PRMT5WDR77NAMPTDRD2DRD3 | |
| SCHEMBL6081560 | 0.76 | NAMPT (0.72) | PRMT5WDR77NAMPTKMT2AMEN1 | |
| SCHEMBL22545842 | 0.74 | PRMT5 (0.59) | PRMT5WDR77DRD2DRD3 | |
| SCHEMBL17117223 | 0.74 | NAMPT (0.82) | NAMPTKMT2AMEN1NPC1TDP1 | |
| SCHEMBL1193818 | 0.74 | NAMPT (0.61) | PRMT5WDR77NAMPTKMT2AMEN1 | |
| SCHEMBL3704595 | 0.74 | NAMPT (0.82) | NAMPTKMT2AMEN1NPC1TDP1 | |
| SCHEMBL8382600 | 0.73 | NAMPT (0.63) | PRMT5WDR77NAMPTKMT2AMEN1 | |
| SCHEMBL17117322 | 0.73 | NAMPT (0.82) | NAMPTKMT2AMEN1NPC1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | claimed |
| EP-2227461-A1 | NEW COMPOUNDS III | AstraZeneca AB (Publ) (SE) | 2010-09-15 | — | — | EP | disclosed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | disclosed |
| WO-2009071677-A1 | NEW COMPOUNDS III | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176798-A1 | New compounds III | GPR119, FABP4, GLP1R | PRMT5 1890/4885WDR77 2024/4885NAMPT 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.